[18F] Fluoromethylated Choline Analogs as Oncologic Radiotracers
Technology Duke University is seeking a company interested in commercializing novel 18F-labeled analogs of choline for imaging. Positron Emission Tomography (PET) is uniquely suited to evaluate metabolic activity in human neoplasms for diagnostic imaging purposes. The glucose analog 18F Fluoro-2-deoxy-glucose (FDG) has proven successful for detection of many types of cancers. However, FDG-PET has been found to have less sensitivity and/or specificity for assessment of certain cancer types, motivating efforts to develop new oncologic tracers for PET. The technology under development is a 18F-labeled choline analogs and methods to synthesize them.
Intellectual Property US Patent No.: 6,630,125
Interested in this Technology?
Submit your interest below.